pharma · Rheumatoid arthritis · Completely Resected Stage IIB, IIC, and III Melanoma
Celltrion Healthcare Australia
Celltrion Healthcare Australia Pty Ltd
Celltrion Healthcare Australia clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Sydney, AU
- Employees
- 9
- Programs
- 10
- Drugs
- 44
- Patents
- 0
Celltrion Healthcare Australia projects
6 ClinicalTrials.gov programs sponsored by Celltrion Healthcare Australia.
Celltrion Healthcare Australia has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CT-L03-301
Celltrion Healthcare Australia Pty Ltd
Type 2 diabetes mellitus (T2DM)
1 trial -
CT-P13 3.11
Celltrion Healthcare Australia Pty Ltd
Rheumatoid arthritis
1 trial -
CT-P44 3.1
Celltrion Healthcare Australia Pty Ltd
Refractory or Relapsed Multiple Myeloma
1 trial -
CT-P51 3.1
Celltrion Healthcare Australia Pty Ltd
Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
1 trial -
CT-P55 3.1
Celltrion Healthcare Australia Pty Ltd
Plaque psoriasis
1 trial -
Trastuzumab
Celltrion Healthcare Australia Pty Ltd
HER2-positive Carcinoma of Breast
1 trial
Frequently asked questions
How many clinical projects does Celltrion Healthcare Australia have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.